Craig Paterson

Dr. Craig Paterson

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


3 June 2020 in Vascular Medicine
Verified
Journal Article
Open access
PDF file
Lee StonerLee Stoner
Lee Stoner
KSKeeron Stone
Keeron Stone
GZGabriel Zieff
Gabriel Zieff
JBJade Blackwell
Jade Blackwell
JDJake Diana
Jake Diana
SFSimon Fryer
Simon Fryer
Flow-mediated slowing (FMS), defined as the minimum pulse wave velocity (PWVmin) during reactive hyperemia, is potentially a simple, user-objective test for examining endothelial function. The purpose of the current study was to determine the effects of a known endothelial dysfunction protocol on arm PWV and PWVmin. Complete data were successfully collected in 22 out of 23 healthy adults (23.8 years [SD 4.1], 16 F, 22.8 kg/m2 [SD 2.8]). Local endothelial dysfunction was induced by increasing retrograde shear stress in the upper arm, through inflation of a distal (forearm) tourniquet to 75 mmHg, for 30 min. Pre- and post-endothelial dysfunction, PWV was measured followed by simultaneous assessment of PWVmin and flow-mediated dilation (FMD). PWV was measured between the upper arm and wrist using an oscillometric device, and brachial FMD using ultrasound. FMD (%) and PWVmin (m/s) were calculated as the maximum increase in diameter and minimum PWV during reactive hyperemia, respectively. Endothelial dysfunction resulted in a large effect size (ES) decrease in FMD (∆ = −3.10%; 95% CI: –4.15, –2.05; ES = −1.3), and a moderate increase in PWV (∆ = 0.38 m/s; 95% CI: 0.07, 0.69; ES = 0.5) and PWVmin (∆ = 0.16 m/s; 95% CI: 0.05, 0.28; ES = 0.6). There was a large intra-individual (pre- vs post-endothelial dysfunction) association between FMD and PWVmin ( r = −0.61; 95% CI: –0.82, –0.24). In conclusion, acute change in PWV and PWVmin are at least partially driven by changes in endothelial function.

1 January 2022 in Atherosclerosis
Verified
Journal Article
Closed access
KSKeeron Stone
Keeron Stone
Simon FryerSimon Fryer
Simon Fryer
JFJames Faulkner
James Faulkner
MMMichelle L. Meyer
Michelle L. Meyer
KHKevin Heffernan
Kevin Heffernan
Lee StonerLee Stoner
Lee Stoner


2 May 2025 in Addiction
Verified
Journal Article
Open access
MHMonika Halicka
Monika Halicka
TPThomas L. Parkhouse
Thomas L. Parkhouse
KWKatie Webster
Katie Webster
FSFrancesca Spiga
Francesca Spiga
LHLindsey A. Hines
Lindsey A. Hines
DCDeborah M. Caldwell
Deborah M. Caldwell
Aim: To evaluate the effectiveness, safety and cost‐effectiveness of psychosocial interventions for cannabis use disorder (CUD).Methods: A systematic review of randomized controlled trials (RCTs; PROSPERO protocol CRD42024553382) of psychosocial interventions for CUD lasting >4 sessions, delivered synchronously, to individuals with CUD aged ≥16 years, in inpatient, outpatient or community‐based settings. We searched databases (MEDLINE/PsycInfo/Cochrane CENTRAL) to 12 June 2024. We assessed results using Risk of Bias 2 and conducted pairwise meta‐analyses. Primary outcomes were continuous‐ and point‐abstinence and withdrawal intensity at the end of treatment, treatment completion and adverse events.Results: We included 22 RCTs (3304 participants). Relative to an inactive/non‐specific comparator, cognitive‐behavioural therapy with motivation enhancement (MET‐CBT) increased point abstinence [odds ratio (OR) = 18.27; 95% confidence interval (9.00−37.07)] and continuous abstinence [OR = 2.72; (1.20−6.19)], but reduced treatment completion [OR = 0.53; (0.35−0.85)]. Dialectical behavioural/acceptance and commitment therapy increased point abstinence versus inactive/non‐specific comparator [OR = 4.34; (1.74−10.80)]. The effect of MET‐CBT plus affect management versus MET‐CBT on point abstinence was OR = 7.85 (0.38−163.52). The effect of MET‐CBT plus abstinence‐based contingency management versus MET‐CBT on point abstinence was OR = 3.78 (0.83−17.25), and on continuous abstinence OR = 1.81 (0.61−5.41). For MET‐CBT plus abstinence‐contingency management versus MET‐CBT plus attendance‐contingency management, the effect on point abstinence was OR = 1.61 (0.72−3.60), and on continuous abstinence OR = 2.04 (0.75−5.58). The effect of community reinforcement on point abstinence was OR = 0.29 (0.04−1.90) versus MET‐CBT, and on continuous abstinence OR = 47.36 (16.00−140.21) versus non‐specific comparator. Interventions other than MET‐CBT may not affect treatment completion. No adverse events were reported. No study reported withdrawal intensity. Two economic evaluations reported higher costs for more complex interventions and contingency management.Conclusions: Cognitive‐behavioural therapy with motivation enhancement and dialectical behavioural/acceptance and commitment therapy may increase abstinence among people with cannabis use disorder relative to an inactive/non‐specific comparator. The conclusions remain tentative due to low‐ to very low‐certainty evidence and the small number of studies.